News BenevolentAI to power small molecule drug discovery Deal with MRCT will look for potential new drug targets and candidates.
News AZ prepares to file blood pressure drug after trial win Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
